Crystal deal tombstone, featuring a cutout of a human brain, marking a follow-on offering by NeuroOne Meidcal Technologies. The Minnesota-based company’s technology targets patients suffering from neurological disorders. (25AKL138)
Crystal deal tombstone, featuring a cutout of a human brain, marking a follow-on offering by NeuroOne Meidcal Technologies. The Minnesota-based company’s technology targets patients suffering from neurological disorders. (25AKL138)
Crystal financial tombstone marking the acquisition of Adapted Nutrition, which specializes in the keto supplements market. (21ALJ612)
Custom Lucite celebrating the approval by the U.S. Food and Drug Administration (FDA) of the drug Crenessity. Crenessity was developed by Neurocrine Biosciences to treat a rare congenital adrenal condition. (25ALJ020)
Custom crystal, incorporating a pharma vial design, celebrating the successful initial public offering on the Euronext Growth Oslo exchange of Oncoinvent. The Oslo-based company is focused on cancer treatments. (25LNL007)
Crystal deal tombstone, incorporating two logo cutouts, marking the acquisition of two Missouri-based manufacturers of surgical instruments. (22ALJ096)
Crystal deal tombstone celebrating Series A funding for Gather Heath, a Massachusetts-based primary care practice focused on older adults. (24AZH136)
Custom Lucite deal toy, replicating a spray bottle product, commemorating a follow-on stock offering by Novabay Pharmaceuticals. The Emeryville, California-based biopharmaceutical company develops products for the eye care market. (24AKL343)
